Table II.
YAP expression | |||
---|---|---|---|
Clinicopathological features | Low, n=65 | Over, n=42 | P-valuea |
Age | |||
<60 | 28 | 22 | 0.428 |
≥60 | 37 | 20 | |
Sex | |||
Male | 51 | 36 | 0.449 |
Female | 14 | 6 | |
Smoking | |||
No | 34 | 19 | 0.554 |
Yes | 31 | 23 | |
Drinking | |||
No | 35 | 23 | 0.926 |
Yes | 30 | 19 | |
Differentiation | |||
Well | 18 | 9 | 0.146 |
Moderate | 36 | 19 | |
Poor | 11 | 14 | |
T stage | |||
T1-2 | 31 | 15 | 0.238 |
T3-4 | 34 | 27 | |
N stage | |||
N0 | 40 | 16 | 0.029b |
N1-3 | 25 | 26 | |
pTNM | |||
I–II | 42 | 19 | 0.071 |
III | 23 | 23 | |
Adjuvant treatment | |||
None | 35 | 28 | 0.417 |
Radiotherapy | 13 | 4 | |
Chemotherapy | 5 | 4 | |
CRT | 12 | 6 |
χ2 test.
P<0.05. CRT, radiochemotherapy; T stage, invasion depth; N stage, lymph node metastasis; pTNM, pathological TNM.